NEOVACS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.98 EUR | -1.00% |
|
-1.00% | -1.00% |
| Sales 2021 | 22.54K 24.1K 1.93M | Sales 2022 | 1.11K 1.19K 95.21K | Capitalization | 102K 109K 8.72M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -11.76M -942M | Net income 2022 | -3M -3.21M -257M | EV / Sales 2021 | - |
| Net cash position 2021 | 32.06M 34.27M 2.74B | Net cash position 2022 | 5.55M 5.94M 476M | EV / Sales 2022 | - |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-
| Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0.12% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.00% |
NEOVACS has become a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. With its innovative technology inducing a polyclonal immune response, protected by four patent families potentially until 2038, NEOVACS focuses its clinical efforts on the development of IFN?-Kinoid for treating lupus. The group also carries out preclinical work on other therapeutic vaccines to treat autoimmune diseases, cancer, allergies and type 1 diabetes.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ALNEV Stock
- ALNEV Stock
